Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.01%
#2 0G 0G +28.35%
#3 Fake World Assets Fake World Assets +21.86%
#4 Full Moon Full Moon +17.70%
#5 Zora Zora +17.60%
#6 SAFEcoin SAFEcoin +17.38%
#7 Notcoin Notcoin +16.69%
#8 Nockchain Nockchain +15.63%
#9 ADO Protocol ADO Protocol +15.62%
#10 Axelar Axelar +13.79%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Pozycja w akcjach #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Cena akcji
$8.46
Ostatnia synchronizacja: 2026-08-28
Kapitalizacja rynkowa
$514.33M
Zmiana (1 dzień)
-2.08%
Zmiana (1 rok)
128.03%
Kraj
US
Handel Kyverna Therapeutics, Inc. (KYTX)

Kategoria

Healthcare
Zyski dla Kyverna Therapeutics, Inc. (KYTX)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Kyverna Therapeutics, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Kyverna Therapeutics, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH